DK1133316T3 - Adenovirus-formulering til genterapi - Google Patents
Adenovirus-formulering til genterapiInfo
- Publication number
- DK1133316T3 DK1133316T3 DK99960405T DK99960405T DK1133316T3 DK 1133316 T3 DK1133316 T3 DK 1133316T3 DK 99960405 T DK99960405 T DK 99960405T DK 99960405 T DK99960405 T DK 99960405T DK 1133316 T3 DK1133316 T3 DK 1133316T3
- Authority
- DK
- Denmark
- Prior art keywords
- infectivity
- adenovirus
- gene therapy
- adenovirus formulation
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10860698P | 1998-11-16 | 1998-11-16 | |
US13311699P | 1999-05-07 | 1999-05-07 | |
PCT/US1999/027177 WO2000029024A1 (en) | 1998-11-16 | 1999-11-16 | Formulation of adenovirus for gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1133316T3 true DK1133316T3 (da) | 2009-05-25 |
Family
ID=26806075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99960405T DK1133316T3 (da) | 1998-11-16 | 1999-11-16 | Adenovirus-formulering til genterapi |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP1133316B1 (da) |
AT (1) | ATE421337T1 (da) |
AU (1) | AU1729600A (da) |
CA (1) | CA2350890C (da) |
DE (1) | DE69940354D1 (da) |
DK (1) | DK1133316T3 (da) |
ES (1) | ES2323991T3 (da) |
WO (1) | WO2000029024A1 (da) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001023001A2 (en) * | 1999-09-29 | 2001-04-05 | The Trustees Of The University Of Pennsylvania | Rapid peg-modification |
JP4550421B2 (ja) | 2001-12-12 | 2010-09-22 | メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド | ウイルスの保存のための組成物 |
GB2408750B (en) * | 2003-12-02 | 2008-12-10 | Arthur A Codd | Preservation of biological material |
CA2555412C (en) | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Virus purification methods |
US20080102524A1 (en) | 2004-06-14 | 2008-05-01 | Ishihara Sangyo Kaisha, Ltd. | Freeze-Dried Composition of Inactivated Virus Envelope with Membrane Fusion Activity |
US8574595B2 (en) | 2005-04-11 | 2013-11-05 | Crucell Holland B.V. | Virus purification using ultrafiltration |
CN101360821A (zh) * | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
BRPI0718548A2 (pt) | 2006-11-07 | 2013-11-12 | Sanofi Pasteur Biologics Co | Estabilização de vacinas por liofilização |
WO2010060719A1 (en) | 2008-11-03 | 2010-06-03 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
AU2011214262B2 (en) | 2010-02-15 | 2015-05-21 | Crucell Holland B.V. | Method for the production of Ad26 adenoviral vectors |
ES2708989T3 (es) | 2010-03-31 | 2019-04-12 | Stabilitech Biopharma Ltd | Método de conservación de adyuvantes de alumbre y vacunas potenciadas con alumbre |
EP2898890B1 (en) | 2010-03-31 | 2019-08-21 | Stabilitech Biopharma Ltd | Stabilisation of viral particles |
KR101884953B1 (ko) | 2010-03-31 | 2018-08-02 | 스타빌리테크 리미티드 | 바이러스 입자, 폴리펩타이드 또는 생물학적 물질의 안정화를 위한 부형제 |
FR2960781B1 (fr) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue |
BR112013005049A2 (pt) * | 2010-09-02 | 2016-05-31 | Sanofi Pasteur | estabilizador para a preparação de uma composição vacina da pólio seca injetável |
EP2618838A1 (en) | 2010-09-20 | 2013-07-31 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
US9168292B2 (en) | 2010-09-27 | 2015-10-27 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
JP6034797B2 (ja) | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク,インコーポレーテッド | 凍結乾燥されたウイルス製剤 |
KR101875245B1 (ko) | 2010-12-02 | 2018-08-02 | 온콜리틱스 바이오테크 인코포레이티드 | 액체 바이러스 제형 |
EP2678020A4 (en) * | 2011-02-24 | 2015-07-22 | Paxvax Inc | FORMULATIONS FOR SPRAY DRIPPING VACCINES |
GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
JP5770952B2 (ja) | 2012-03-12 | 2015-08-26 | クルセル ホランド ベー ヴェー | 改変末端を有する組換えアデノウイルスのバッチ |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
CN103316356B (zh) * | 2012-03-22 | 2016-08-17 | 北京三诺佳邑生物技术有限责任公司 | 一种重组慢病毒载体制剂 |
CN102755325B (zh) * | 2012-07-04 | 2013-05-29 | 深圳信立泰药业股份有限公司 | 一种头孢西丁钠药物组合物、其粉针剂及其制备方法 |
SI2988780T1 (sl) | 2013-04-25 | 2019-05-31 | Janssen Vaccines & Prevention B.V. | Stabilizirani topni prefuzijski RSV F polipeptidi |
MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
PE20160527A1 (es) * | 2013-09-19 | 2016-05-20 | Crucell Holland Bv | Formulaciones de adenovirus mejoradas |
GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
WO2016154055A1 (en) * | 2015-03-20 | 2016-09-29 | Bluebird Bio, Inc. | Vector formulations |
JP6735288B2 (ja) | 2015-04-14 | 2020-08-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 双方向性プロモーターを有する2つの導入遺伝子を発現する組換えアデノウイルス |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
DK3319633T3 (da) | 2015-07-07 | 2021-02-01 | Janssen Vaccines & Prevention Bv | Vaccine mod rsv |
CN105219645B (zh) * | 2015-11-06 | 2018-09-25 | 南京农业大学 | 一种微生物保护剂及其应用 |
KR102491447B1 (ko) | 2016-04-05 | 2023-01-20 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
CA3018941A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f proteins |
EP3464331B1 (en) | 2016-05-30 | 2020-10-28 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
RU2745500C2 (ru) | 2016-06-20 | 2021-03-25 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
CN108703952B (zh) * | 2018-08-16 | 2021-05-07 | 张志刚 | 一种猪瘟口服弱毒冻干疫苗用冻干保护剂及应用 |
AR118734A1 (es) * | 2019-04-19 | 2021-10-27 | Regenxbio Inc | Formulaciones y métodos de vectores de virus adenoasociados |
US20220290179A1 (en) * | 2019-08-29 | 2022-09-15 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
CN116096732A (zh) | 2020-01-31 | 2023-05-09 | 贝斯以色列护理医疗中心有限公司 | 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗 |
JP2024509756A (ja) | 2021-02-19 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前rsv fb抗原 |
WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0761955B2 (ja) * | 1988-04-28 | 1995-07-05 | 国立予防衛生研究所長 | 凍結乾燥a型肝炎ワクチン |
ES2188593T3 (es) * | 1992-03-24 | 2003-07-01 | United Cancer Res Inst | Vacuna que contiene un virus vivo. |
US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
CA2158935A1 (en) * | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
JPH09508017A (ja) * | 1994-01-12 | 1997-08-19 | ジェネティック セラピー,インコーポレイテッド | レトロウイルスベクターの精製 |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
EP1760151B1 (en) * | 1996-11-20 | 2012-03-21 | Crucell Holland B.V. | Adenovirus compositions obtainable by an improved production and purification method |
US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
KR100912362B1 (ko) * | 1998-02-17 | 2009-08-19 | 쉐링 코포레이션 | 바이러스 제제의 정제방법 |
-
1999
- 1999-11-16 ES ES99960405T patent/ES2323991T3/es not_active Expired - Lifetime
- 1999-11-16 DK DK99960405T patent/DK1133316T3/da active
- 1999-11-16 DE DE69940354T patent/DE69940354D1/de not_active Expired - Lifetime
- 1999-11-16 EP EP99960405A patent/EP1133316B1/en not_active Expired - Lifetime
- 1999-11-16 WO PCT/US1999/027177 patent/WO2000029024A1/en active Application Filing
- 1999-11-16 EP EP08006162A patent/EP1977764A1/en not_active Withdrawn
- 1999-11-16 AU AU17296/00A patent/AU1729600A/en not_active Abandoned
- 1999-11-16 AT AT99960405T patent/ATE421337T1/de active
- 1999-11-16 CA CA2350890A patent/CA2350890C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2000029024A9 (en) | 2000-11-02 |
DE69940354D1 (de) | 2009-03-12 |
ES2323991T3 (es) | 2009-07-28 |
EP1133316B1 (en) | 2009-01-21 |
EP1977764A1 (en) | 2008-10-08 |
CA2350890C (en) | 2014-07-08 |
WO2000029024A1 (en) | 2000-05-25 |
CA2350890A1 (en) | 2000-05-25 |
ATE421337T1 (de) | 2009-02-15 |
AU1729600A (en) | 2000-06-05 |
EP1133316A1 (en) | 2001-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1133316T3 (da) | Adenovirus-formulering til genterapi | |
DE69729786D1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
DK0722313T3 (da) | Viskoelastiske sammensætninger af fluorerede organiske forbindelser | |
LT2001041A (en) | Stable liquid formulations of botulinum toxin | |
DK1117440T3 (da) | Farmaceutiske sammensætninger indeholdende paclitaxel | |
DK0812198T3 (da) | Stabilisering af prostaglandinpræparater | |
ATE387492T1 (de) | Verfahren und zusammensetzung zur konservierung von adenoviren | |
NO991974L (no) | 5-HT1F agonister | |
TR199903036T2 (xx) | Kararl� insulin form�lasyonlar�. | |
ID26033A (id) | Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan | |
BR0009951A (pt) | Composição de higiene pessoal | |
PT758248E (pt) | Formulacoes para o factor ix | |
ATE481497T1 (de) | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a | |
DE69717815T2 (de) | Verbesserungen von kreatin-zusammensetzungen | |
EE9800248A (et) | Külmkuivatatud, vesiikuleid sisaldav ultraheli kontrastaine, selle valmistamismeetod ning ladustamise ja transpordi meetod, ultraheli kontrastaine keskkond ja selle valmistamismeetod ning külmkuivatuse stabilisaatorite kasutamine | |
PT1163008E (pt) | Utilizacao de trealose para estabilizacao de uma vacina liquida | |
CY1105185T1 (el) | Σταθepα σκευασματα ινσουλινης | |
BRPI0418115A (pt) | formulação lìquida estável de hormÈnio de crescimento | |
BR0007201A (pt) | Composições incluindo agentes de preservação demalto-oligossacarìdeos reduzidos, e métodospara preservar um material | |
BRPI0417366A (pt) | composição detergente lìquida, método de limpeza de um substrato de tecido, e, uso de um antioxidante | |
DE60116359D1 (de) | Kahalalid f formulierung | |
GT199900129A (es) | Formulaciones liquidas de pirimetanilo y metodos para su preparacion. | |
DE60232271D1 (de) | Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen | |
WO2022109294A3 (en) | Rna stabilization | |
ES2180319T3 (es) | Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos. |